Accurate models for P-gp drug recognition induced from a cancer cell line cytotoxicity screen

Journal of Medicinal Chemistry

Volumn 56, Issue 14, 2013, Pages 5691-5708

  Levatić, Jurica ^a   Ćurak, Jasna ^a   Kralj, Marijeta ^a,b   Šmuc, Tomislav ^a,b   Osmak, Maja ^b   Supek, Fran ^a,b  

^a BioZyne Ltd   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CHLORAMBUCIL; COLCHICINE; CP 100356; CYTOTOXIC AGENT; DIGITOXIGENIN; ESTRONE; ETOPOSIDE; FIRTECAN; FLUOROURACIL; GLYCOPROTEIN P INHIBITOR; MERCAPTOPURINE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ACCURACY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOLECULAR MODEL; MOLECULAR RECOGNITION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SUPPORT VECTOR MACHINE;

CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; P-GLYCOPROTEIN; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; VINCRISTINE;

EID: 84880906307     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400328s     Document Type: Article

References (79)

1. Fromm, M. F. Importance of P-glycoprotein at blood-tissue barriers Trends Pharmacol. Sci. 2004, 25, 423-429
2. Zhou, S.-F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition Xenobiotica 2008, 38, 802-832
3. Shoemaker, R. H. Genetic and epigenetic factors in anticancer drug resistance J. Natl. Cancer Inst. 2000, 92, 4-5
4. Szakács, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer Nat. Rev. Drug Discovery 2006, 5, 219-234
5. Szakács, G.; Váradi, A.; Özvegy-Laczka, C.; Sarkadi, B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox) Drug Discovery Today 2008, 13, 379-393
6. Penzotti, J. E.; Lamb, M. L.; Evensen, E.; Grootenhuis, P. D. J. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein J. Med. Chem. 2002, 45, 1737-1740
7. Seelig, A. A general pattern for substrate recognition by P-glycoprotein Eur. J. Biochem. 1998, 251, 252-261
8. Xue, Y.; Yap, C. W.; Sun, L. Z.; Cao, Z. W.; Wang, J. F.; Chen, Y. Z. Prediction of P-glycoprotein substrates by a support vector machine approach J. Chem. Inf. Comput. Sci. 2004, 44, 1497-1505
9. Cabrera, M. A.; González, I.; Fernández, C.; Navarro, C.; Bermejo, M. A topological substructural approach for the prediction of P-glycoprotein substrates J. Pharm. Sci. 2006, 95, 589-606
10. Wang, Z.; Chen, Y.; Liang, H.; Bender, A.; Glen, R. C.; Yan, A. P-glycoprotein substrate models using support vector machines based on a comprehensive data set J. Chem. Inf. Model. 2011, 51, 1447-1456
11. Bikadi, Z.; Hazai, I.; Malik, D.; Jemnitz, K.; Veres, Z.; Hari, P.; Ni, Z.; Loo, T. W.; Clarke, D. M.; Hazai, E.; Mao, Q. Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein PLoS One 2011, 6 e25815
12. Didziapetris, R.; Japertas, P.; Avdeef, A.; Petrauskas, A. Classification analysis of P-glycoprotein substrate specificity J. Drug Targeting 2003, 11, 391-406
13. Chen, L.; Li, Y.; Yu, H.; Zhang, L.; Hou, T. Computational models for predicting substrates or inhibitors of P-glycoprotein Drug Discovery Today 2012, 17, 343-351
14. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S. Rational use of in vitro P-glycoprotein assays in drug discovery J. Pharmacol. Exp. Ther. 2001, 299, 620-628
15. Mechetner, E.; Kyshtoobayeva, A.; Zonis, S.; Kim, H.; Stroup, R.; Garcia, R.; Parker, R. J.; Fruehauf, J. P. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin Clin. Cancer Res. 1998, 4, 389-398
16. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2002, 2, 48-58
17. Bioinformatics & Evolutionary Genomics. http://bioinformatics.psb. ugent.be/webtools/Venn/ (accessed Jan, 2012).
18. De Cerqueira Lima, P.; Golbraikh, A.; Oloff, S.; Xiao, Y.; Tropsha, A. Combinatorial QSAR modeling of P-glycoprotein substrates J. Chem. Inf. Model. 2006, 46, 1245-1254
19. Svetnik, V.; Wang, T.; Tong, C.; Liaw, A.; Sheridan, R. P.; Song, Q. Boosting: an ensemble learning tool for compound classification and QSAR modeling J. Chem. Inf. Model. 2005, 45, 786-799
20. Huang, J.; Ma, G.; Muhammad, I.; Cheng, Y. Identifying P-glycoprotein substrates using a support vector machine optimized by a particle swarm J. Chem. Inf. Model. 2007, 47, 1638-1647
21. Ivanciuc, O. Applications of Support Vector Machines in Chemistry. In Reviews in Computational Chemistry; Lipkowitz, K. B.; Cundari, T. R., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2007; pp 291-400.
22. Gredičak, M.; Supek, F.; Kralj, M.; Majer, Z.; Hollósi, M.; Šmuc, T.; Mlinarić-Majerski, K.; Horvat, Š. Computational structure-activity study directs synthesis of novel antitumor enkephalin analogs Amino Acids 2010, 38, 1185-1191
23. Supek, F.; Ramljak, T. Š.; Marjanović, M.; Buljubašić, M.; Kragol, G.; Ilić, N.; Šmuc, T.; Zahradka, D.; Mlinarić-Majerski, K.; Kralj, M. Could LogP be a principal determinant of biological activity in 18-crown-6 ethers? Synthesis of biologically active adamantane-substituted diaza-crowns Eur. J. Med. Chem. 2011, 46, 3444-3454
24. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834
25. Seelig, A.; Landwojtowicz, E. Structure-activity relationship of P-glycoprotein substrates and modifiers Eur. J. Pharm. Sci. 2000, 12, 31-40
26. Yasuda, K.; Lan, L.; Sanglard, D.; Furuya, K.; Schuetz, J. D.; Schuetz, E. G. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein J. Pharmacol. Exp. Ther. 2002, 303, 323-332
27. Crivori, P.; Reinach, B.; Pezzetta, D.; Poggesi, I. Computational models for identifying potential P-glycoprotein substrates and inhibitors Mol. Pharmaceutics 2006, 3, 33-44
28. Szakács, G.; Annereau, J.-P.; Lababidi, S.; Shankavaram, U.; Arciello, A.; Bussey, K. J.; Reinhold, W.; Guo, Y.; Kruh, G. D.; Reimers, M.; Weinstein, J. N.; Gottesman, M. M. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells Cancer Cell 2004, 6, 129-137
29. Alvarez, M.; Paull, K.; Monks, A.; Hose, C.; Lee, J. S.; Weinstein, J.; Grever, M.; Bates, S.; Fojo, T. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen J. Clin. Invest. 1995, 95, 2205-2214
30. Wallqvist, A.; Rabow, A. A.; Shoemaker, R. H.; Sausville, E. A.; Covell, D. G. Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data Bioinformatics 2003, 19, 2212-2224
31. Ke, W.; Yu, P.; Wang, J.; Wang, R.; Guo, C.; Zhou, L.; Li, C.; Li, K. MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research Med. Oncol. 2011, 28 (Suppl. 1) S135-141
32. Roschke, A. V.; Tonon, G.; Gehlhaus, K. S.; McTyre, N.; Bussey, K. J.; Lababidi, S.; Scudiero, D. A.; Weinstein, J. N.; Kirsch, I. R. Karyotypic complexity of the NCI-60 drug-screening panel Cancer Res. 2003, 63, 8634-8647
33. Garraway, L. A.; Widlund, H. R.; Rubin, M. A.; Getz, G.; Berger, A. J.; Ramaswamy, S.; Beroukhim, R.; Milner, D. A.; Granter, S. R.; Du, J.; Lee, C.; Wagner, S. N.; Li, C.; Golub, T. R.; Rimm, D. L.; Meyerson, M. L.; Fisher, D. E.; Sellers, W. R. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma Nature 2005, 436, 117-122
34. Steinbeck, C.; Han, Y.; Kuhn, S.; Horlacher, O.; Luttmann, E.; Willighagen, E. The chemistry development kit (CDK): an open-source Java library for chemo- and bioinformatics J. Chem. Inf. Comput. Sci. 2003, 43, 493-500
35. Gombar, V. K.; Polli, J. W.; Humphreys, J. E.; Wring, S. A.; Serabjit-Singh, C. S. Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model J. Pharm. Sci. 2004, 93, 957-968
36. Zhao, Y. H.; Abraham, M. H.; Zissimos, A. M. Fast calculation of van der Waals volume as a sum of atomic and bond contributions and its application to drug compounds J. Org. Chem. 2003, 68, 7368-7373
37. Mannhold, R.; Poda, G. I.; Ostermann, C.; Tetko, I. V. Calculation of molecular lipophilicity: state-of-the-art and comparison of log P methods on more than 96,000 compounds J. Pharm. Sci. 2009, 98, 861-893
38. Szegezdi, J.; Csizmadia, F. Prediction of Distribution Coefficient Using Microconstants. Presented at the 227th National Meeting of the American Chemical Society, Anaheim, CA, Mar 28-Apr 1, 2004.
39. Osmak, M.; Beketić-Orešković, L.; Matulić, M.; Sorić, J. Resistance of human larynx carcinoma cells to cisplatin, γ-irradiation and methotrexate does not involve overexpression of c-myc or c-Ki-ras oncogenes Mutat. Res. Lett. 1993, 303, 113-120
40. Barretina, J.; Caponigro, G.; Stransky, N.; Venkatesan, K.; Margolin, A. A.; Kim, S.; Wilson, C. J.; Lehár, J.; Kryukov, G. V.; Sonkin, D.; Reddy, A.; Liu, M.; Murray, L.; Berger, M. F.; Monahan, J. E.; Morais, P.; Meltzer, J.; Korejwa, A.; Jané-Valbuena, J.; Mapa, F. A.; Thibault, J.; Bric-Furlong, E.; Raman, P.; Shipway, A.; Engels, I. H.; Cheng, J.; Yu, G. K.; Yu, J.; Aspesi, P.; de Silva, M.; Jagtap, K.; Jones, M. D.; Wang, L.; Hatton, C.; Palescandolo, E.; Gupta, S.; Mahan, S.; Sougnez, C.; Onofrio, R. C.; Liefeld, T.; MacConaill, L.; Winckler, W.; Reich, M.; Li, N.; Mesirov, J. P.; Gabriel, S. B.; Getz, G.; Ardlie, K.; Chan, V.; Myer, V. E.; Weber, B. L.; Porter, J.; Warmuth, M.; Finan, P.; Harris, J. L.; Meyerson, M.; Golub, T. R.; Morrissey, M. P.; Sellers, W. R.; Schlegel, R.; Garraway, L. A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 2012, 483, 603-307
41. Garnett, M. J.; Edelman, E. J.; Heidorn, S. J.; Greenman, C. D.; Dastur, A.; Lau, K. W.; Greninger, P.; Thompson, I. R.; Luo, X.; Soares, J.; Liu, Q.; Iorio, F.; Surdez, D.; Chen, L.; Milano, R. J.; Bignell, G. R.; Tam, A. T.; Davies, H.; Stevenson, J. A.; Barthorpe, S.; Lutz, S. R.; Kogera, F.; Lawrence, K.; McLaren-Douglas, A.; Mitropoulos, X.; Mironenko, T.; Thi, H.; Richardson, L.; Zhou, W.; Jewitt, F.; Zhang, T.; O'Brien, P.; Boisvert, J. L.; Price, S.; Hur, W.; Yang, W.; Deng, X.; Butler, A.; Choi, H. G.; Chang, J. W.; Baselga, J.; Stamenkovic, I.; Engelman, J. A.; Sharma, S. V.; Delattre, O.; Saez-Rodriguez, J.; Gray, N. S.; Settleman, J.; Futreal, P. A.; Haber, D. A.; Stratton, M. R.; Ramaswamy, S.; McDermott, U.; Benes, C. H. Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 2012, 483, 570-575
42. Gupta, P. B.; Onder, T. T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R. A.; Lander, E. S. Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell 2009, 138, 645-659
43. Miller, S. J.; Lavker, R. M.; Sun, T.-T. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications Biochim. Biophys. Acta 2005, 1756, 25-52
44. Vogel, C.; Abreu, R. de S.; Ko, D.; Le, S.-Y.; Shapiro, B. A.; Burns, S. C.; Sandhu, D.; Boutz, D. R.; Marcotte, E. M.; Penalva, L. O. Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line Mol. Syst. Biol. 2010, 6 400
45. Supek, F.; Šmuc, T. On relevance of codon usage to expression of synthetic and natural genes in Escherichia coli Genetics 2010, 185, 1129-1134
46. Greenman, C. D.; Bignell, G.; Butler, A.; Edkins, S.; Hinton, J.; Beare, D.; Swamy, S.; Santarius, T.; Chen, L.; Widaa, S.; Futreal, P. A.; Stratton, M. R. PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data Biostatistics 2010, 11, 164-175
47. Cancer Genome Project Gene Copy Number Analysis. http://www.sanger.ac.uk/ cgi-bin/genetics/CGP/cghviewer/CghHome.cgi (accessed Jul 2012).
48. Cancer Genome Project Gene Copy Number Analysis, NCI/ADR-RES Chromosome 7. http://www.sanger.ac.uk/cgi-bin/genetics/CGP/cghviewer/CghViewer.cgi?action= DisplayChromosome&tissue=breast&d=2&chr=7&id=6582 (accessed Jul, 2012).
49. Cancer Genome Project Gene Copy Number Analysis, OVCAR-8 Chromosome 7. http://www.sanger.ac.uk/cgi-bin/genetics/CGP/cghviewer/CghViewer.cgi?action= DisplayChromosome&d=2&chr=7&id=6707 (accessed Jul, 2012).
50. Desai, P. V.; Sawada, G. A.; Watson, I. A.; Raub, T. J. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux Mol. Pharmaceutics 2013, 10, 1249-1261
51. Österberg, T.; Norinder, U. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics Eur. J. Pharm. Sci. 2000, 10, 295-303
52. Zamora, J. M.; Pearce, H. L.; Beck, W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells Mol. Pharmacol. 1988, 33, 454-462
53. Pawagi, A. B.; Wang, J.; Silverman, M.; Reithmeier, R. A. F.; Deber, C. M. Transmembrane aromatic amino acid distribution in P-glycoprotein: a functional role in broad substrate specificity J. Mol. Biol. 1994, 235, 554-564
54. Pajeva, I. K.; Wiese, M. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis) J. Med. Chem. 2002, 45, 5671-5686
55. Seelig, A.; Landwojtowicz, E.; Fischer, H.; Li Blatter, X. Towards P-Glycoprotein Structure-Activity Relationships. In Drug Bioavailability; van de Waterbeemd, H.; Lennernäs, H.; Artursson, P., Eds.; Wiley-VCH: Weinheim, Germany, 2004; pp 461-492.
56. Dolghih, E.; Bryant, C.; Renslo, A. R.; Jacobson, M. P. Predicting binding to P-glycoprotein by flexible receptor docking PLoS Comput. Biol. 2011, 7, e1002083
57. Li, W.-X.; Li, L.; Eksterowicz, J.; Ling, X. B.; Cardozo, M. Significance analysis and multiple pharmacophore models for differentiating P-glycoprotein substrates J. Chem. Inf. Model. 2007, 47, 2429-2438
58. Poongavanam, V.; Haider, N.; Ecker, G. F. Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors Bioorg. Med. Chem. 2012, 20, 5388-5395
59. Kelly, R. J.; Draper, D.; Chen, C. C.; Robey, R. W.; Figg, W. D.; Piekarz, R. L.; Chen, X.; Gardner, E. R.; Balis, F. M.; Venkatesan, A. M.; Steinberg, S. M.; Fojo, T.; Bates, S. E. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer Clin. Cancer Res. 2011, 17, 569-580
60. Maki, N.; Hafkemeyer, P.; Dey, S. Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation J. Biol. Chem. 2003, 278, 18132-18139
61. Rautio, J.; Humphreys, J. E.; Webster, L. O.; Balakrishnan, A.; Keogh, J. P.; Kunta, J. R.; Serabjit-Singh, C. J.; Polli, J. W. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates Drug Metab. Dispos. 2006, 34, 786-792
62. Wang, Y.-H.; Li, Y.; Yang, S.-L.; Yang, L. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach J. Chem. Inf. Model. 2005, 45, 750-757
63. Broccatelli, F.; Carosati, E.; Neri, A.; Frosini, M.; Goracci, L.; Oprea, T. I.; Cruciani, G. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields J. Med. Chem. 2011, 54, 1740-1751
64. Lu, X.; Gong, S.; Monks, A.; Zaharevitz, D.; Moscow, J. A. Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity J. Exp. Ther. Oncol. 2002, 2, 200-212
65. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen Nat. Rev. Cancer 2006, 6, 813-823
66. Downloadable Structure Files of NCI Open Database Compounds. http://cactus.nci.nih.gov/download/nci/ (accessed Dec 2012).
67. O'Boyle, N.; Banck, M.; James, C.; Morley, C.; Vandermeersch, T.; Hutchison, G. Open Babel: an open chemical toolbox J. Cheminf. 2011, 3, 1-14
68. Chang, C.-C.; Lin, C.-J. LIBSVM: A library for support vector machines ACM Trans. Intell. Syst. Technol. 2011, 2, 27:1-27:27
69. EL-Manzalawy, Y.; Honavar, V. WLSVM: Integrating LibSVM into Weka Environment; Iowa State University: Ames, IA, 2005; software available at http://www.cs.iastate.edu/∼yasser/wlsvm.
70. Hsu, C.-W.; Chang, C.-C.; Chih-Jen, L. A Practical Guide to Support Vector Classification; National Taiwan University: Tapei, Taiwan, 2010; available at http://www.csie.ntu.edu.tw/∼cjlin/papers/guide/guide.pdf.
71. Fawcett, T. An introduction to ROC analysis Pattern Recognit. Lett. 2006, 27, 861-874
72. Klekota, J.; Roth, F. P. Chemical substructures that enrich for biological activity Bioinformatics 2008, 24, 2518-2525
73. Cohen, W. W. Fast Effective Rule Induction. In Proceedings of the Twelfth International Conference on Machine Learning; Morgan Kaufmann Publishers, 1995; pp 115-123.
74. Hall, M.; Frank, E.; Holmes, G.; Pfahringer, B.; Reutemann, P.; Witten, I. H. The WEKA data mining software: an update SIGKDD Explor. Newsl. 2009, 11, 10-18
75. Osmak, M. Collateral resistance or sensitivity of human larynx carcinoma HEp2 cells resistant to cis-dichlorodiammineplatinum (II) or vincristine sulfate Neoplasma 1992, 39, 197-202
76. Supek, F.; Kralj, M.; Marjanović, M.; Šuman, L.; Šmuc, T.; Krizmanić, I.; Žinić, B. Atypical cytostatic mechanism of N -1-sulfonylcytosine derivatives determined by in vitro screening and computational analysis Invest. New Drugs 2008, 26, 97-110
77. Ester, K.; Supek, F.; Majsec, K.; Marjanović, M.; Lembo, D.; Donalisio, M.; Šmuc, T.; Jarak, I.; Karminski-Zamola, G.; Kralj, M. Putative mechanisms of antitumor activity of cyano-substituted heteroaryles in HeLa cells Invest. New Drugs 2012, 30, 450-467
78. Lavie, Y.; Cao, H. t; Volner, A.; Lucci, A.; Han, T. Y.; Geffen, V.; Giuliano, A. E.; Cabot, M. C. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells J. Biol. Chem. 1997, 272, 1682-1687
79. Zhao, P.; Kunze, K. L.; Lee, C. A. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes Drug Metab. Dispos. 2005, 33, 853-861